According to a recent LinkedIn post from C Ray Therapeutics, the company is drawing attention to localized alpha therapies as a potential solution to the challenge of treating peritoneal metastases in ovarian and gastrointestinal cancers. The post notes limitations of systemic chemotherapy and conventional radioligand therapies in penetrating poorly vascularized peritoneal surfaces and highlights a shift in focus from drug potency to delivery geometry.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights the upcoming XDC Conference 2026 in Chengdu, where Oncoinvent ASA CEO Oystein Soug is expected to discuss Ra-224–based localized alpha therapy targeting micrometastases in the abdominal cavity. The session is described as emphasizing receptor-independent mechanisms, the short path length and high linear energy transfer of alpha particles, and strategies for retaining alpha-emitting payloads within the peritoneal cavity.
As co-organizer of the International RDC Sub-Forum at XDC 2026, C Ray Therapeutics suggests that localized alpha therapy will require a diversified radiopharmaceutical manufacturing toolkit and scalable, GMP-compliant production. For investors, this focus may indicate that the company is positioning itself within a niche of regional radiopharmaceutical delivery and advanced CDMO capabilities, potentially aligning with growing demand for specialized oncology manufacturing and collaboration opportunities in nuclear medicine.